<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SYNGENE</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SYNGENE</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="syngene-international-limited" class="section level1">
<h1>Syngene International Limited</h1>
<p><a href="/reports01/index/industry/rp-HealthcareResearchAnalyticsTechnology.html">Healthcare Research Analytics &amp; Technology</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNGENE.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="syngene-international-limited-syngene-analysis" class="section level3">
<h3>Syngene International Limited (SYNGENE) Analysis</h3>
<p>Syngene International Ltd. (NSE: SYNGENE, BSE: 539268), an integrated Contract Research, Development, and Manufacturing Organization (CRDMO), reported Q2 FY26 (ended Sep 30, 2025) revenue of Rs 911 Cr (+2% YoY, +4% QoQ) and H1 FY26 revenue of Rs 1,785 Cr (+6% YoY). EBITDA margins contracted to 22-23% (down ~400-500 bps YoY) due to higher staff costs, forex losses, and biologics inventory adjustments, leading to PAT decline (Q2: -37% YoY to Rs 67 Cr; H1: -4% YoY to Rs 154 Cr before exceptional items). The company maintains FY26 guidance amid strategic expansions. Below is a structured analysis based on the provided filings (financial results, investor presentation, press release, etc.).</p>
<div id="tailwinds-positive-factors" class="section level6">
<h6><strong>Tailwinds (Positive Factors)</strong></h6>
<ul>
<li><strong>Revenue Momentum &amp; Diversification</strong>: Steady top-line growth driven by research services (discovery, clinical trials) offsetting biologics inventory corrections. H1 revenue up 6% YoY; ~USD 204 Mn. Strong client base (~400 active clients, 14/20 top pharma cos like BMS, Amgen, Zoetis).</li>
<li><strong>Strategic Wins &amp; Expansions</strong>: First global Phase III trial (US biotech, India/US sites); clinical footprint expanded to Australia, NZ, UK, Sri Lanka, E. Europe. New GMP bioconjugation suite for end-to-end ADCs; US Bayview biologics facility on track for H2 FY26 ops. Total bioreactor capacity to 50kL post-acquisitions.</li>
<li><strong>Sustainability Edge</strong>: Top ESG ratings (EcoVadis 74/100, 91st percentile; My Green Lab ‘Green Certification’ &gt;94%; TIME’s ‘World’s Most Sustainable Cos 2025’ #1 Indian pharma/biotech). 92% renewable energy; appeals to global clients.</li>
<li><strong>Financial Strength</strong>: Net cash Rs 10,183 Mn; robust balance sheet (equity Rs 47,349 Mn). Supports capex in high-growth modalities (peptides, oligos, PROTACs, ADCs).</li>
<li><strong>Operational Excellence</strong>: 5,641 scientists (68% of 8,235 headcount); digitized ops, AI integration, 111 audits passed (strong compliance: USFDA/EMA approved).</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<ul>
<li><strong>Margin Pressure</strong>: EBITDA margin down to 23% (H1) from 25% YoY due to +13-14% staff costs (33% of revenue), forex loss (Rs 166 Mn H1), higher depreciation from new capex. PAT margins at 8.5% (H1).</li>
<li><strong>Biologics Inventory Drag</strong>: Temporary correction in manufacturing revenue; offset by research services but highlights cyclicality.</li>
<li><strong>Forex Volatility</strong>: Rs 277 Mn receivables write-off (Rs 202 Mn post-tax) due to cumulative FX changes; net FX loss Rs 118 Mn in Q2.</li>
<li><strong>Macro Environment</strong>: US biotech funding slowdown (improving but recent); impacts emerging biotech revenue share (14% in FY25).</li>
<li><strong>Capex Intensity</strong>: High CWIP (Rs 9,892 Mn); delays in US site revalidation/staffing could pressure near-term cash flows (H1 op cash flow negative at -Rs 451 Mn consolidated).</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<ul>
<li><strong>High-Growth Platforms</strong>: 3-pronged strategy – Research Services (SynVent/SARchitect platforms), Large Molecule CDMO (50kL capacity, Zoetis partnership), Small Molecule CDMO. New modalities (ADCs, peptides) position for 10-15%+ industry growth.</li>
<li><strong>Capacity Ramp-Up</strong>: Doubled infra since FY16 (2.5 Mn sq ft); Hyderabad land bank, Mangalore API, US biologics for commercial-scale. Emerging biotech contribution rising (10% FY21 to 14% FY25).</li>
<li><strong>Clinical Expansion</strong>: Phase III win signals shift to higher-value trials; global partnerships enhance execution.</li>
<li><strong>Guidance &amp; Outlook</strong>: FY26 revenue/EBITDA/PAT guidance intact despite Q2 pressures. Long-term: Integrated end-to-end services reduce client switching; 400+ patents with clients.</li>
<li><strong>M&amp;A Synergies</strong>: Recent Stelis/Emergent acquisitions bolster multi-modal capabilities; potential for more.</li>
</ul>
<p><strong>Projected Growth</strong>: Medium-term revenue CAGR 10-15% feasible (FY25: Rs 3,642 Cr), driven by biologics ramp (post-H2 FY26) and new modalities. EPS trajectory tied to margin recovery to 25-28%.</p>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="37%" />
<col width="32%" />
<col width="30%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Forex &amp; FX Exposure</strong></td>
<td>High USD revenue (clients US/EU/Japan); Q2 loss Rs 118 Mn, receivables write-off. Rupee volatility impacts PAT.</td>
<td>Hedging (derivatives Rs 830 Mn assets); China-independent supply chain.</td>
</tr>
<tr class="even">
<td><strong>Execution/Regulatory</strong></td>
<td>Delays in US facility ops, new suites; 111 audits but past fire incident (2016 insurance settled).</td>
<td>Proven track record (5 USFDA audits); GLP/AAALAC accredited.</td>
</tr>
<tr class="odd">
<td><strong>Client/Concentration</strong></td>
<td>Reliance on big pharma (BMS 25-yr pact); biotech funding cycles.</td>
<td>Diversified (400 clients, sectors: pharma/biotech/nutrition); FTE/FFS/risk-reward models.</td>
</tr>
<tr class="even">
<td><strong>Margin Erosion</strong></td>
<td>Staff costs up 14% YoY; depreciation from capex.</td>
<td>OpEx focus (Six Sigma, digital SynPro); guidance assumes recovery.</td>
</tr>
<tr class="odd">
<td><strong>Competition</strong></td>
<td>Global CRDMOs (Lonza, Catalent); India peers.</td>
<td>Integrated model, cost advantage, ESG leadership.</td>
</tr>
<tr class="even">
<td><strong>Macro/Geopolitical</strong></td>
<td>US biotech slowdown; India regulatory changes (IEPF dividends reminder signals compliance).</td>
<td>Agile BD in US/EU; 92% green energy buffers ESG regs.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Risk Profile</strong>: Moderate; strong balance sheet/governance offsets execution risks. No UPSI disclosures in analyst meets.</p>
</div>
<div id="summary" class="section level6">
<h6><strong>Summary</strong></h6>
<p><strong>Bull Case</strong>: Tailwinds from expansions (ADCs/US biologics), clinical wins, and ESG dominance drive 12-15% revenue CAGR; margins rebound to 26%+ by FY27 on capacity utilization. Target: Upside to Rs 850-900 (current ~Rs 625 implied from mkt cap Rs 2,51,000 Mn). <strong>Bear Case</strong>: Prolonged biotech funding winter + FX/margin pressures cap FY26 growth at 5-8%; PAT flat. <strong>Recommendation</strong>: <strong>Hold/Buy on Dips</strong>. Maintain FY26 guidance signals resilience; H2 recovery likely. Monitor US biotech funding and Q3 results (investor call Nov 6, 2025). Strong fundamentals (net cash, client stickiness) support long-term outperformance in CRDMO space.</p>
<p><em>Analysis based solely on provided docs; cross-check latest market data.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
